Innovation & intellectual property · 16/01/2014Updated: 10/17/2026 · 1 min read
USPTO Grants Interim Extension to INTERCEPT Blood System Patent
Summary
The US Patent and Trademark Office has granted a one-year interim extension to the term of U.S. Patent No. 5,593,823 for the INTERCEPT Blood System for Plasma, allowing the patent to remain in effect until at least 2025.
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →